Santhera Pharmaceuticals AG Announces Start of US Phase III Clinical Trial with SNT-MC17 in Friedreich’s Ataxia and Provides Details on Study Design

LIESTAL, SWITZERLAND--(Marketwire - September 28, 2007) - Initiation of a six month study with 51 FRDA patients and ICARS as primary endpoint expected shortly. Fast-track designation granted by FDA.